a neat and clean solution

Hi,

I think the following solution will work out in everyone's interest!

1. Solagran strikes a deal to buy all SLA (56111895) and SLACF (10132865) from ANZ say at average of 0.25c for SLA and 0.20c for SLACF. Given the number of shares, this will be a sensible deal both for Solagran and ANZ.

2. Solagran keep these shares as treasury stock (as NZO has done for 10% of their stock). Solagran is still takeover proof with this treasury stock.

3. Solagran need approx $16 to $17 Million to buy this parcel from ANZ. We should have around ($7 million cash after options are excercised later this month - $5 M from options and $2 M from Contributing just collected in Feb). The rest of cash can be raised by selling Ropren in advance at a discount for first three months supply.

4. Solagran calls an EGM and decides to allocate the shares back to the Solamind shareholdings in their proportion (in return they agree to remain with Solagran research team). This can be allocated over say 5 years with stiff shareprice hurdles.

5. Solgarn distributes around 80% profit in dividends for first 5 years. This will ensure that other shareholders get more propotionate of divi while Solamind shareholders miss quite a bit (first year they will have only 20% shares etc). So we get extra rewards while they also get shafted for divi.

6. The company only returns the shares as per their holding. The excess can be still retained by company treasury or cancelled out (resulting in approx 10% reduction in shares issued). Again the shareholders will benefit.

Any thoughts on this scenario!

This way everyone wins. The company is protected from takeover, no share hangover and if company meets strict hurdles, we as well as Solamind win.

If Solagran buys shares, this will still allow Solamind to have the right to sue ANZ (if so desired by them).